Pulmonx Corporation (LUNG)
Pulmonx Corporation is a medical technology company focused on minimally invasive treatments for chronic obstructive pulmonary diseases. Their Zephyr Valve and related technologies aim to improve the lives of patients with severe emphysema.
Company Overview
Pulmonx Corporation (LUNG) offers innovative, minimally invasive solutions for severe emphysema, highlighted by the Zephyr Valve, targeting a significant unmet need in respiratory care and demonstrating a commitment to improving patient outcomes globally, despite current financial headwinds.
Investment Thesis
Investing in Pulmonx Corporation (LUNG) presents a compelling opportunity, albeit with inherent risks. The company's Zephyr Valve addresses a significant unmet need in the treatment of severe emphysema, offering a minimally invasive alternative to surgery. Despite a negative P/E ratio of -1.08 and a profit margin of -61.9%, the high gross margin of 73.3% indicates the potential for profitability as the company scales. Key value drivers include increased adoption of the Zephyr Valve, driven by positive clinical data and growing awareness among physicians and patients. Growth catalysts include expansion into new markets and continued innovation in respiratory care technologies. The company's low beta of 0.07 suggests relatively low volatility compared to the broader market. Success hinges on Pulmonx's ability to navigate regulatory hurdles, secure reimbursement coverage, and effectively commercialize its products.
Key Highlights
- Gross margin of 73.3% indicates strong pricing power and efficient production despite overall losses.
- Serves patients in the United States, Europe, the Middle East, Africa, and the Asia-Pacific, demonstrating global market reach.
- Offers StratX Lung Analysis Platform, a cloud-based service, enhancing treatment planning and precision.
- Zephyr Endobronchial Valve provides a minimally invasive alternative to surgery for severe emphysema patients.
- Chartis Pulmonary Assessment System aids in identifying suitable candidates for Zephyr Valve treatment, improving patient outcomes.
Competitors
Strengths
- Innovative Zephyr Valve technology.
- Minimally invasive approach.
- Strong clinical evidence.
- Global market presence.
Weaknesses
- Negative profitability.
- Reliance on a single product.
- Limited market awareness.
- Reimbursement challenges.
Catalysts
- Upcoming: Publication of new clinical data supporting the Zephyr Valve's efficacy (Q3 2026).
- Ongoing: Expansion of reimbursement coverage for the Zephyr Valve in key markets.
- Ongoing: Increased adoption of the StratX Lung Analysis Platform by pulmonologists.
- Upcoming: Potential FDA approval for new indications of the Zephyr Valve (H2 2026).
Risks
- Potential: Competition from established medical device companies.
- Potential: Regulatory setbacks or delays.
- Ongoing: Reimbursement challenges from payers.
- Ongoing: Product liability claims.
- Potential: Economic downturn affecting hospital budgets.
Growth Opportunities
- Expansion into New Geographic Markets: Pulmonx has the opportunity to expand its presence in underserved markets, particularly in Asia-Pacific and Latin America. These regions have a growing prevalence of COPD and emphysema, coupled with increasing healthcare spending. By establishing partnerships with local distributors and conducting targeted marketing campaigns, Pulmonx can tap into these new markets and drive revenue growth. This expansion could contribute significantly to revenue within the next 3-5 years.
- Increased Adoption of Zephyr Valve in Existing Markets: Despite its proven efficacy, the Zephyr Valve is still underutilized in many existing markets. Pulmonx can increase adoption by educating physicians about the benefits of the Zephyr Valve, providing training and support, and securing favorable reimbursement coverage from payers. Increased awareness and access will drive higher procedure volumes and revenue growth. This is an ongoing opportunity with continuous potential for improvement.
- Development of Next-Generation Technologies: Pulmonx can leverage its expertise in respiratory care to develop next-generation technologies that address unmet needs in the treatment of COPD and other lung diseases. This could include new valve designs, improved diagnostic tools, or novel drug delivery systems. Investing in research and development will allow Pulmonx to maintain its competitive edge and capture new market share. Expect to see initial results from R&D in the next 2-3 years.
- Strategic Partnerships and Acquisitions: Pulmonx can accelerate its growth by forming strategic partnerships with other companies in the respiratory care space. This could include collaborations with pharmaceutical companies, diagnostic device manufacturers, or telehealth providers. Acquisitions of complementary technologies or businesses could also expand Pulmonx's product portfolio and market reach. Such partnerships could materialize within the next year, leading to synergistic growth.
- Enhanced Patient Selection and Treatment Planning: Pulmonx's StratX Lung Analysis Platform provides valuable information for patient selection and treatment planning. By further refining this platform and integrating it with other diagnostic tools, Pulmonx can improve patient outcomes and reduce the risk of complications. This will enhance the value proposition of the Zephyr Valve and drive increased adoption. Continuous improvement of the platform is an ongoing opportunity.
Opportunities
- Expansion into new markets.
- Development of next-generation technologies.
- Strategic partnerships.
- Increased adoption of Zephyr Valve.
Threats
- Competition from alternative treatments.
- Regulatory hurdles.
- Economic downturn.
- Product liability risks.
Competitive Advantages
- Proprietary Zephyr Endobronchial Valve technology.
- Extensive clinical data supporting the efficacy of the Zephyr Valve.
- Established relationships with key opinion leaders in respiratory care.
- StratX Lung Analysis Platform provides a competitive advantage in patient selection.
About
Pulmonx Corporation, founded in 1995 and headquartered in Redwood City, California, is a medical technology company dedicated to developing and commercializing minimally invasive devices for the treatment of chronic obstructive pulmonary diseases (COPD), particularly severe emphysema. The company's flagship product is the Zephyr Endobronchial Valve, a small, one-way valve implanted in the airways to block airflow to diseased regions of the lung, allowing healthier areas to expand and improve breathing. This innovative solution offers a less invasive alternative to traditional surgical options for patients with hyperinflation associated with severe emphysema. In addition to the Zephyr Valve, Pulmonx offers the Chartis Pulmonary Assessment System, which helps physicians assess collateral ventilation in the lungs to determine patient suitability for Zephyr Valve treatment. The StratX Lung Analysis Platform, a cloud-based service, provides quantitative CT analysis to aid in identifying target lobes for Zephyr Valve placement. Pulmonx serves patients across the United States, Europe, the Middle East, Africa, and the Asia-Pacific region, demonstrating its global reach and commitment to addressing the needs of emphysema patients worldwide. The company changed its name from Pulmonx to Pulmonx Corporation in December 2013, reflecting its evolution and growth in the medical device industry.
What They Do
- Develops and commercializes minimally invasive medical devices.
- Offers the Zephyr Endobronchial Valve for treating severe emphysema.
- Provides the Chartis Pulmonary Assessment System to assess collateral ventilation.
- Offers the StratX Lung Analysis Platform for CT image analysis.
- Helps physicians identify suitable patients for Zephyr Valve treatment.
- Improves breathing and quality of life for emphysema patients.
- Provides a less invasive alternative to surgical lung volume reduction.
Business Model
- Sells Zephyr Endobronchial Valves to hospitals and clinics.
- Generates revenue from the sale of Chartis Pulmonary Assessment Systems.
- Offers the StratX Lung Analysis Platform as a service.
- Provides training and support to physicians using its products.
Industry Context
Pulmonx operates within the medical device industry, specifically targeting the respiratory care market. The prevalence of COPD and emphysema is increasing globally, driven by factors such as aging populations and smoking. The market for minimally invasive treatments for respiratory diseases is growing, as patients and physicians seek alternatives to traditional surgery. Pulmonx competes with companies offering other bronchoscopic and surgical interventions for emphysema. Key trends in the industry include technological advancements in diagnostic and therapeutic devices, a focus on personalized medicine, and increasing demand for cost-effective healthcare solutions. The competitive landscape includes companies like Acrivon Therapeutics (ACRV), but Pulmonx differentiates itself with its unique Zephyr Valve technology and comprehensive approach to patient selection and treatment planning.
Key Customers
- Hospitals and clinics specializing in respiratory care.
- Pulmonologists and thoracic surgeons.
- Emphysema patients with severe hyperinflation.
- Healthcare providers in the United States, Europe, and Asia-Pacific.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $22M | -$14M | $0.00 |
| Q2 2025 | $24M | -$15M | $0.00 |
| Q1 2025 | $23M | -$14M | $0.00 |
| Q4 2024 | $24M | -$13M | $0.00 |
Source: Company filings
Chart & Info
Price Chart
Pulmonx Corporation (LUNG) stock price: $1.50 (+0.00, +0.00%)
Why Bull
- •Insider buying has increased recently, suggesting confidence in the company's future prospects.
- •Community sentiment has shifted positively, with discussions highlighting Pulmonx's innovative technologies in lung treatment.
- •Recent partnerships have expanded their market reach, enhancing their competitive positioning.
- •Analysts have noted a growing awareness of lung health issues, potentially increasing demand for Pulmonx's solutions.
Why Bear
- •Concerns about regulatory hurdles persist, as the healthcare sector faces increased scrutiny from authorities.
- •Community discussions reflect skepticism regarding the scalability of Pulmonx's products in a competitive market.
- •Recent earnings reports showed slower growth than expected, raising doubts about future performance.
- •Market sentiment remains cautious due to broader economic uncertainties affecting healthcare spending.
Latest News
-
Magnolia Medical Welcomes Sarah Huber as Senior Vice President, Sales
PR Newswire · Feb 12, 2026
-
Magnolia Medical Welcomes Sarah Huber as Senior Vice President, Sales
Yahoo! Finance: LUNG News · Feb 12, 2026
-
SOPHiA GENETICS (NASDAQ:SOPH) versus Pulmonx (NASDAQ:LUNG) Critical Comparison
defenseworld.net · Feb 1, 2026
-
Analyzing Pulmonx (NASDAQ:LUNG) and Privia Health Group (NASDAQ:PRVA)
defenseworld.net · Jan 26, 2026
Technical Analysis
Rationale
AI-generated technical analysis for LUNG including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Pulmonx Corporation (LUNG) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for LUNG.
Make a Prediction
Set your price target for Pulmonx Corporation (LUNG), choose a timeframe, and track your prediction accuracy.
Current price: $1.50
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LUNG.
Price Targets
Wall Street price target analysis for LUNG.
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 6/100
Revenue increased 22.0% YoY, reflecting moderate but steady business growth.
-
Gross Margin 10/100
Gross margin of 73.3% shows excellent pricing power and a strong competitive moat.
-
Operating Leverage 6/100
Revenue growth is driving operating leverage, meaning profits can grow faster than costs.
-
Cash Runway 5/100
Cash position data is currently unavailable for this company.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 5/100
Float and volume data unavailable for liquidity analysis.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates LUNG's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Magnolia Medical Welcomes Sarah Huber as Senior Vice President, Sales
Magnolia Medical Welcomes Sarah Huber as Senior Vice President, Sales
SOPHiA GENETICS (NASDAQ:SOPH) versus Pulmonx (NASDAQ:LUNG) Critical Comparison
Analyzing Pulmonx (NASDAQ:LUNG) and Privia Health Group (NASDAQ:PRVA)
Frequently Asked Questions
What does Pulmonx Corporation do?
Pulmonx Corporation is a medical technology company focused on developing and commercializing minimally invasive devices for the treatment of chronic obstructive pulmonary diseases (COPD), particularly severe emphysema. Their primary product is the Zephyr Endobronchial Valve, a small device implanted in the airways to block airflow to diseased regions of the lung, allowing healthier areas to expand and improve breathing. They also offer the Chartis Pulmonary Assessment System to assess patient suitability and the StratX Lung Analysis Platform for CT image analysis, providing a comprehensive approach to treating emphysema patients globally.
Is LUNG stock a good buy?
LUNG stock presents a speculative investment opportunity. While the company's Zephyr Valve addresses a significant unmet need and boasts a high gross margin of 73.3%, Pulmonx is currently unprofitable with a negative P/E ratio and profit margin. Potential investors should consider the company's growth prospects, driven by increased adoption of the Zephyr Valve and expansion into new markets, against the risks of competition, reimbursement challenges, and regulatory hurdles. A thorough assessment of the company's financial position and market dynamics is crucial before investing.
What are the main risks for LUNG?
Pulmonx faces several key risks. Competition from established medical device companies and alternative treatments for emphysema poses a threat to market share. Regulatory setbacks or delays in obtaining approvals for new products or indications could hinder growth. Reimbursement challenges from payers may limit patient access to the Zephyr Valve. Product liability claims are an inherent risk in the medical device industry. An economic downturn could affect hospital budgets and reduce demand for Pulmonx's products. These factors could negatively impact the company's financial performance and stock price.
How does the StratX Lung Analysis Platform benefit Pulmonx and its customers?
The StratX Lung Analysis Platform is a cloud-based service that provides quantitative computed tomography (CT) analysis, offering valuable information on emphysema destruction, fissure completeness, and lobar volume. This helps physicians identify target lobes for treatment with Zephyr Valves, leading to improved patient selection and outcomes. For Pulmonx, the platform enhances the value proposition of the Zephyr Valve, drives increased adoption, and potentially generates recurring revenue through service fees. It also strengthens Pulmonx's competitive advantage by providing a comprehensive solution for emphysema treatment planning.
Is LUNG a good stock to buy?
Whether LUNG is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.
What is the LUNG MoonshotScore?
The MoonshotScore for LUNG is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.
How often is LUNG data updated?
LUNG stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to LUNG is aggregated continuously from premium financial news sources throughout the day.
What are the growth catalysts for LUNG?
Growth catalysts for Pulmonx Corporation (LUNG) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Pulmonx Corporation's specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.
Who are LUNG's main competitors?
Pulmonx Corporation (LUNG) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether LUNG has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.
What do analysts say about LUNG?
Wall Street analyst coverage for LUNG includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.
What is LUNG's market cap?
Market capitalization (market cap) for LUNG is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows LUNG's current market cap alongside enterprise value and other valuation metrics.
How has LUNG stock performed recently?
LUNG's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing LUNG's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.
What are the risks of investing in LUNG?
Key risk categories for LUNG include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures LUNG's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.
Are insiders buying or selling LUNG?
Insider trading activity for LUNG tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.
Is LUNG a good stock for beginners?
Pulmonx Corporation (LUNG) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Financial data may be slightly outdated. Stock data pending update.